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A B S T R A C T
The aim of the randomised, double blind, placebo controlled study was to evaluate the efficacy, tolerability and safety
of solifenacin, a once-daily M3 selective receptor antagonist, in patients with overactive bladder syndrome. Following a
single blind 2-week placebo run in period, patients who complained from symptoms of OAB for at least 6 months, were
randomized to 4 weeks of solifenacin in 5 mg once daily doses or placebo. 171 patients were enrolled in the study and 157
patients completed the study. Patients with solifenacin had significantly improved micturitions per 24 hours after first
week of treatment (1.75±0.63 vs. 2.64±0.48, p<0.001), and after four weeks (1.56±0.58 vs. 2.71±0.45, p<0.001)compared
to placebo group. The mean number of urgency episodes per 24 hours had significantly decreased in patients with solife-
nacin compared to placebo after first week (5.75±1.43 vs. 6.65±0.65, p<0.001), and after four weeks of treatment (5.77±
1.33 vs. 6.54±0.50, p<0.001). Solifenacin was also significantly more effective than placebo in reducing the mean num-
ber of episodes of severe urgency from baseline to end point (5.83±1.16 vs. 6.48±0.50, p<0.001). Compared with changes
obtained with placebo, episodes of urinary frequency were significanlty reduced after first week (0.3 vs. –0.5, p<0.001)
and four weeks check up periods in patients treated with solifenacin (0.19 vs. –0.15, p<0.001). Episodes of nocturia was
significantly reduced in patients treated with solifenacin after first week (0.3 vs. –0.5, p<0.001), and after four weeks
treatment period (0.45 vs. –0.50, p<0.001). The number of incontinence episodes was also significantly decreased in
solifenacin group compared to placebo group after first week (1.06±0.57 vs. 2.74±0.47, p<0.001) and four weeks check up
(0.96±0.57 vs. 2.75±0.43, p<0.001). The most common adverse effects with solifenacin were dry mouth and constipation.
Adverse effects were mild or moderate severity. The discontinuation rate owing to adverse effects was 4.5%–6.7% with
solifenacin and 3.8%–6.1% with placebo, respectively. According to subjective estimation, significant improvement was
achieved in 71 (92.21%) of patients treated with solifenacin and in 68(85%) patients treated with placebo there was no
change in OAB symptoms compared to baseline values. UDI score was significantly improved after solifenacin (22.26±
5.91 vs. 29.61±8.45, p<0.001) compared to placebo. IIQ score was significantly decreased in patients with solifenacin
(36.25±10.34 vs. 46.86±6.81, p<0.001) compared to placebo. In conclusion, solifenacin is a safe and effective treatment
alternative for patients with overactive bladder symptoms.
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Introduction
Overactive bladder syndrome (OAB) has been defined
by the International Continence Society as a complex
cascade of symptoms that includes urinary urgency, with
or without urge incontinence, usually accompanied by
urinary frequency and nocturia1. These symptoms are
associated with significant morbidity and often have a
profound impact on patient quality of life2–5. Antimusca-
rinic therapy represents the most common treatment for
patients with OAB6–7. They have been proven to be the
most effective agents in supressing premature detrusor
contractions, enhacing bladder storage, and relieving
symptoms. Several antimuscarinic agents are currently
available for the treatment of OAB in adults, including
oxybutynin, tolterodine, trospium chloride, darifenacin
and solifenacin1,5–9. Although all are deemed to be effec-
tive in improving the bothersome symptoms of OAB,
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they differ in their molecular properties, metabolism,
and tolerability/side effect profile. Solifenacin is new spe-
cific antimuscarinic drug which compared with oxybuty-
nin and tolterodine have more favourable side effects
profile which enhance tolerability and patient compli-
ance. In recent clinical trials solifenacin has shown supe-
riority to placebo and equal efficacy as oxybutynin and
tolterodine1–5. The aim of the study is to evaluate the effi-
cacy, tolerability and safety of solifenacin, a once-daily
M3 selective receptor antagonist in patients with overac-
tive bladder syndrome.
Material and Methods
Following a single blind 2-week placebo run in period,
patients were randomized to 4 weeks of solifenacin in 5
mg once daily doses or placebo. 171 patients were en-
rolled in the study and 157 patients completed the study.
Patients who complained from symptoms of OAB for at
least 6 months were included in the randomised, dou-
ble-blind, placebo controlled study. Inclusion criterias are
urge incontinence (at least but no more than 50 episodes
per week), frequency of micturition (at least eight voids
per 24 hours) and urgency (a strong desire to void at least
once per day). Patients were excluded from the study if
they had contraindications for the use of antimuscarinic
drugs (e.g. uncontrolled narrow-angle glaucoma, urinary
or gastric retention), clinically significant stress urinary
incontinence (more than one episode per week), clinically
significant bladder outlet obstruction and /or a post-void
residual volume more than 200 mL, genitourinary condi-
tion that could cause urinary symptoms, recent urogeni-
tal surgery or hepatic disease. Treatment efficacy was
evaluated after one and four weeks treatment periods ac-
cording to subjective assesment using data recorded in
patient diaries in the one and four week periods preced-
ing the scheduled clinical visits. The objective assesment
of treatment efficacy was determined by Urinary inconti-
nence-specific quality of life (QOL) instruments included
the Urinary Distress Inventory (UDI) and Incontinence
Impact Questionnaire (IIQ). Higher UDI and IIQ scale
scores reflect increasing symptom bother and greater im-
pact on daily activities. The primary endpoint for this 12
week trial was the mean change from baseline in the
mean number of micturition episodes, urgency, nocturia,
and incontinence episodes per 24 hours. Safety and tole-
rability of solifenacin were secondary study objectives.
Tolerability and safety data were collected at each visit,
and at other times if volunteered by the patient. All ob-
served or volunteered adverse events were evaluated by
the investigator and the patient in terms of severity, seri-
ousness and potential relationship to treatment were
also evaluated by the investigator. Treatment discon-
tinuations were also assessed for potential relationship
to study treatment. The Ethical Committee of Depart-
ment for Gynecology and Obstetrics Medical School Uni-
versity of Zagreb approved the study protocol and con-
sent forms. Written informed consent was obtained from
each patient. Statistical analysis was performed using
PASW for Windows, 17.02. Preliminary analyses were
performed to ensure no violation of the assumptions of
normality, linearity and homoscedasticity. Numerical va-
riables were tested for the normality of distribution us-
ing Kolmogorov-Smirnov test. Normally distributed vari-
ables were presented as means±standard deviations and
Student’s t-test was used for comparissons between the
groups. Data that were not normally distributed were
presented as medians and Mann-Whitney U-test was
used to evaluate differences between the groups. Data
from different time periods was tested for statistical sig-
nificance with the repeated measures ANOVA or Fried-
man test as appropriate with further analysis carried out
with the paired t-test or Wilcoxon signed rank test. Cate-
gorical data are expressed as numbers and frequences.
The differences between more than 2 groups for categori-
cal data were analysed using Pearson’s chi square, and
Fisher exact test. A P value<0.05 (two sided tests) was
considered to be significant.
Results
From a total of 171 women randomised to solifenacin
or placebo, data from 157 patients were available for the
analysis of efficacy and safety of solifenacin. Baseline
characteristics of OAB patients are summarised in Table
1 and were similar among two treatment groups. At
baseline, there was no difference in voiding parameters
among placebo and solifenacin group (p>0.05). Patients
with solifenacin had significantly improved micturitions
per 24 hours after first week of treatment (1.75±0.63 vs.
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TABLE 1
BASELINE CHARACTERISTICS OF OAB PATIENTS ENTERED
THE STUDY
Variables (X±SD) Solifenacin Placebo
Age (years) 56.77±10.16 57.03±10.05
BMI (body mass index) 29.18±4.06 29.64±4.08
Parity 1.90±1.05 1.95±1.10
Fig. 1. Mean differences in urinary frequency, nocturia, urgency
and micturition per 24 hours from baseline after first week of
treatment.
2.64±0.48, p<0.001), and four weeks compared to pla-
cebo group (1.56±0.58 vs. 2.71±0.45, p<0.001) (Figure
1,2). The mean number of urgency episodes per 24 hours
had significantly decreased in patients with solifenacin
compared to placebo after first week (5.75±1.43 vs. 6.65±
0.65, p<0.001), and after four weeks of treatment (5.77±
1.33 vs. 6.54±0.50, p<0.001) (Figure 1,2). Solifenacin was
also significantly more effective than placebo in reducing
the mean number of episodes of severe urgency from
baseline to end point (5.83±1.16 vs. 6.48±0.50, p<0.001).
Compared with changes obtained with placebo, episodes
of urinary frequency were significanlty reduced after
first week (0.3 vs. –0.5, p<0.001) and four weeks check
up periods in patients treated with solifenacin (0.19 vs.
–0.15, p<0.001) (Figure 1,2). Episodes of nocturia were
significantly reduced in patients treated with solifenacin
after first week (0.3 vs. –0.5, p<0.001), and after four
weeks treatment period (0.45 vs. –0.50, p<0.001) (Figure
1,2). The number of incontinence episodes was also sig-
nificantly decreased in solifenacin group compared to
placebo group after first week (1.06±0.57 vs. 2.74±0.47,
p<0.001) and four weeks check up (0.96±0.57 vs. 2.75±
0.43, p<0.001) (Figure 3). The most common adverse ef-
fects with solifenacin were dry mouth and constipation
(Table 2). Adverse effects were mild or moderate severity.
The discontinuation rate owing to adverse effects was
4.5–6.7% with solifenacin and 3.8–6.1% with placebo, re-
spectively (Figure 4). After first week in 48 (62.34%) pa-
tients with solifenacin was subjectively estimated im-
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TABLE 2
INCIDENCE RATES OF ADVERSE EVENTS AFTER SOLIFENACIN
Frequency Percent (%)
Increase eye pressure 3 3.8
Dry mouth and opstipation 3 3.8
Intestinal disturbances 2 2.6
Dry mouth 2 2.6
Intestinal disturbances and i
blurred vision
1 1.3
Dry mouth and decreased con-
centration
1 1.3
Dry mouth, tremor 1 1.3










Dizziness, blurred vision 1 1.3
Fig. 2. Mean differences in urinary frequency, nocturia, urgency
and micturition per 24 hours from baseline after four weeks of
treatment.
Fig. 3. Incontinence episodes per 24h.
Fig. 4. Incidence of discontinuation rate between solifenacin and
placebo group. Discontinuation rate 1-at baseline, discontinua-
tion rate 2-after treatment.
Fig. 5. Subjective evaluation of treatment outcome after first week,
p<0.001.
provement compared to 66 (82.50%) patients on placebo
who presented no change in micturition problems com-
pared to baseline (p<0.001) (Figure 5). After four weeks
statistically significant improvement was achieved in
71(92.21%) patients with solifenacin compared to 68
(85.00%) patients with placebo who determined no changes
in micturition pattern (Figure 6). According to subjective
estimation, significant improvement was achieved in 71
(92.21%) of patients treated with solifenacin and in 68
(85.00%) patients treated with placebo there was no
change in OAB symptoms compared to baseline values
after three months as shown in Figure 7. UDI score was
significantly improved after solifenacin (22.26±5.91 vs.
29.61±8.45, p<0.001) compared to placebo as presented
in Figure 8. IIQ score was significantly decreased in pa-
tients with solifenacin (36.25±10.34 vs. 46.86±6.81, p<
0.001) compared to placebo (Figure 9).
Discussion and Conclusion
Overactive bladder is a common condition which has
an adverse effect on quality of life. The most commonly
used pharmacologic agents for the treatment of overac-
tive bladder disturbances are the muscarinic receptor an-
tagonists. These included oxybutynin, tolterodine, and
three agents that have recently been approved for the
use i.e. trospium, darifenacin, and solifenacin9,10. Their
action resulted in less uninhibited bladder contractions,
thereby allowing improved bladder filling and reduced
urgency as well as other symptoms of overactive bladder.
The ideal antimuscarinic drug should effectively relieve
the symptoms of OAB with the minimum of side effects.
Furthermore, it should be available as a once-daily sus-
tained release formulation and in dosage strenght that
allows easy dose titration for the majority of patients.
Solifenacin has been shown in both short and long term
clinical trials to fulfill these criterias. In multiple clinical
trials, solifenacin treatment has been associated with
statistically significant reductions in all key symptoms of
OAB (urinary frequency, urgency and incontinence) as
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Fig. 6. Subjective evaluation of treatment outcome after four weeks,
*p<0.001.
Fig. 7. Subjective evaluation of treatment outcome after three
months.
Fig. 8. Comparison of urinary distress inventory before and after
treatment with solifenacin and placebo. UDI 1-urinary distress
inventory at baseline, UDI 2-urinary distress inventory after
treatment.
Fig. 9. Comparison of incontinence impact questionnaire at base-
line and after treatment with solifenacin and placebo. IIQ 1-in-
continence impact questionnaire at baseline, IIQ 2-incontinence
impact questionnare after treatment.
well as increase in volume voided1–10. In particular, it pro-
duces a significant decrease in urgency episodes, which is
the principal symptom of OAB11. Our study confirmed
the efficacy of solifenacin in reducing the number of ur-
gency episodes in patients with OAB. It was effective as
early as day seven of treatment. The mean number of
micturition episodes per 24 hours was also decreased in
patients treated with solifenacin compared to placebo.
The results of our study correlated with results of Car-
dozo et al who also confirmed solifenacin efficacy in re-
ducing the micturition per 24 hours in double blind pla-
cebo controlled study9. Diurnal and nocturnal urinary
frequency are common signs of overactive bladder. Our
data demonstrated the efficacy of solifenacin in 5 mg
once daily doses in reducing diurnal and particularly noc-
turnal frequency. One of the major findings of this study
was the significant reduction in nocturia episodes in pa-
tients taking a 5 mg dose of solifenacin compared to
study of Cardozo et al who demonstrated equal effect but
with solifenacin in 10 mg dosage1. Our study confirmed
results of Chapple et al who found a significant decrease
of incontinence episodes in patients with solifenacin12.
The possible explanation of these benefit is suppresing of
premature detrusor contractions and enhacing of blad-
der storage and maximal cystometric capacity. Despite
potential benefits, primary care clinicians may avoid us-
ing antimuscarinic drugs in women with OAB because of
safety concerns. Oxybutynin, tolterodine, darifenacin,
solifenacin, and trospium antagonize the effects of ace-
tylcholine at muscarinic receptors on the detrusor muscle
and are known as antimuscarinic agents. These agents po-
tently and selectively bind to the M3 receptor subtype
more than other muscarinic receptor subtypes, with the
exception of tolterodine, which has demonstrated no
specificity for any subtype. Solifenacin has demonstrated
greater tissue selectivity for inhibition of detrusor con-
traction over salivation, offering an advantage over other
agents by reducing adverse effects and improving compli-
ance. In our study, treatment with solifenacin was well
tolerated. Dry mouth and opstipation were the most
common adverse effects with solifenacin. Adverse effects
were mild or moderate severity. The discontinuation rate
owing to adverse effects was 4.5–6.7% with solifenacin
and was similar to withdrawal rate in patients treated
with placebo. Urinary incontinence-specific quality of life
(QOL) instruments included the Urinary Distress Inven-
tory (UDI) and Incontinence Impact Questionnaire (IIQ).
Higher UDI and IIQ scale scores reflect increasing symp-
tom bother and greater impact on daily activities13,14.
Both, UDI and IIQ were significantly improved in our pa-
tients treated with solifenacin confirming efficacy in pa-
tients with overactive bladder symptoms. In conclusion,
solifenacin is a well tolerata and effective treatment mo-
dality for patients with overactive bladder.
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U^INKOVITOST I SIGURNOST SOLIFENACINA U LIJE^ENJU BOLESNICA S PREKOMJERNO
AKTIVNIM MOKRA]NIM MJEHUROM
S A @ E T A K
Cilj randomizirane, dvostruko slijepe placebo kontrolirane studije je procjeniti u~inkovitost, podno{ljivost i sigur-
nost solifenacina, selektivnog M3 antagonista u bolesnica s prekomjerno aktivnim mokra}nim mjehurom. Nakon jed-
nostruko slijepog dvotjednog »run in« perioda, bolesnice sa smetnjama prekomjerno aktivnog mokra}nog mjehura u
trajanju od najmanje {est mjeseci randomizirane su na primjenu 5 mg solifenacina ili placeba u trajanju od ~etiri tjedna.
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Od 171 pacijentica uklju~enih u studiju, njih 157 je zavr{ilo istra`ivanje. Bolesnice lije~ene solifenacinom imaju zna-
~ajno bolje mikcijske parametre u usporedbi sa pacijenticama tretiranim placebom. Bolesnice lije~ene solifenacinom
imaju zna~ajno smanjen broj epizoda mikcije na 24 sata nakon prvog tjedna studije (1,75±0,63 vs. 2,64±0,48, p<0,001),
te nakon ~etiri tjedna studije (1,56±0,58 vs. 2,71±0,45, p<0,001) u usporedbi s placebom. Prosje~an broj epizoda urgen-
cije u 24 sata zna~ajno je manji u `ena korisnica solifenacina nakon prvog tjedna ispitivanja (5,75±1,43 vs. 6,65±0,65,
p<0,001) i nakon ~etiri tjedna (5,77±1,33 vs. 6,54±0,50, p<0,001) u usporedbi s placebom. Solifenacin je zna~ajno u~in-
kovitiji u smanjenju epizoda te{ke urgencije u usporedbi s placebom (5,83±1,16 vs. 6,48±0,50, p<0,001). U usporedbi s
placebom, zna~ajno je manji broj epizoda urinarne frekvencije u `ena korisnica solifenacina nakon prvog tjedna (0,3 vs.
–0,5, p<0,001) i nakon ~etvrtog tjedna lije~enja (0,19 vs. –0,15, p<0,001). Broj epizoda nikturije zna~ajno je manji u
`ena koje su lije~ene solifenacinom nakon prvog tjedna lije~enja (0,3 vs. –0,5, p<0,001) i nakon ~etvrtog tjedna lije~enja
(0,45 vs. –0,50, p<0,001). Broj epizoda inkontinencije zna~ajno je smanjen u `ena korisnica solifenacina u usporedbi s
placebom nakon prvog tjedna lije~enja 1,06±0,57 vs. 2,74±0,47, p<0,001) i nakon ~etvrtog tjedna lije~enja (0,96±0,57 vs.
2,75±0,43, p<0,001). Naj~e{}e nuspojave u `ena koje su lije~ene solifenacinom su bile suha usta i opstipacija. Stopa
prekida lije~enja zbog nuspojava iznosila je 4,5%–6,7% za solifenacin i 3,8%–6.1% za placebo. Na temelju subjektivne
procjene, zna~ajno pobolj{anje je postignuto u 71 (92,21%) pacijentica korisnica solifenacina, a u 68 (85%) pacijentica
lije~enih placebom nisu uo~ene promjene u simptomima prekomjerno aktivnog mokra}nog mjehura u odnosu na po~et-
ne vrijednosti. UDI skor je zna~ajno pobolj{an u `ena lije~enih solifenacinom (22,26±5,91 vs. 29,61±8,45, p<0,001) u
usporedbi s placebom. U usporedbi s placebom, IIQ skor je zna~ajno manji u bolesnica koje su primjenjivale solifenacin
36,25±10,34 vs. 46,86±6,81, p<0,001). U zaklju~ku, solifenacin predstavlja sigurnu i u~inkovitu terapijsku alternativu
u lije~enju bolesnica s prekomjerno aktivnim mokra}nim mjehurom.
